Top ▲
Quaternary Structure: Subunits |
Interleukin 1 receptor, type I (Ligand-binding subunit) |
IL-1 receptor accessory protein (Other subunit) |
Database Links | |
SynPHARM | 77163 (in complex with IL-1 receptor antagonist) |
Selected 3D Structures | |||||||||||||
|
Natural/Endogenous Ligands |
IL-1α {Sp: Human} |
IL-1β {Sp: Human} |
IL-1 receptor antagonist {Sp: Human} |
Download all structure-activity data for this target as a CSV file
Inhibitors | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Key to terms and symbols | Click column headers to sort | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Agonists | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Key to terms and symbols | Click column headers to sort | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Antagonists | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Key to terms and symbols | Click column headers to sort | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Immunopharmacology Comments |
Interleukin-1 receptor, type I (IL-1RI) is a heterodimer containing the ligand binding interleukin 1 receptor, type I (IL1R1) subunit and the IL-1 receptor accessory protein (IL1RAP) required for signal transduction. This receptor is primarily responsible for transmitting the inflammatory effects of interleukin-1 (IL-1). Endogenous ligands for this receptor include IL-1α, IL-1β and IL-1RA. IL-1RI signalling is involved in many biological functions; thymocyte proliferation, B cell development, IL-2 and IL-6 production, stress responses, inflammatory responses, sleep regulation, appetite and Th17 deifferentiation. This latter function links IL-1RI signalling with Th17-mediated autoimmune diseases. |
1. Akeson AL, Woods CW, Hsieh LC, Bohnke RA, Ackermann BL, Chan KY, Robinson JL, Yanofsky SD, Jacobs JW, Barrett RW et al.. (1996) AF12198, a novel low molecular weight antagonist, selectively binds the human type I interleukin (IL)-1 receptor and blocks in vivo responses to IL-1. J Biol Chem, 271 (48): 30517-23. [PMID:8940020]
2. Dripps DJ, Verderber E, Ng RK, Thompson RC, Eisenberg SP. (1991) Interleukin-1 receptor antagonist binds to the type II interleukin-1 receptor on B cells and neutrophils. J Biol Chem, 266 (30): 20311-5. [PMID:1834644]
3. Kovalchin J, King B, Masci A, Hopkins E, Fry J, Hou J, Li C, Tenneson K, Weber S, Wolfe G et al.. (2018) Preclinical Development of EBI-005: An IL-1 Receptor-1 Inhibitor for the Topical Ocular Treatment of Ocular Surface Inflammatory Diseases. Eye Contact Lens, 44 (3): 170-181. [PMID:28727604]
4. Schreuder H, Tardif C, Trump-Kallmeyer S, Soffientini A, Sarubbi E, Akeson A, Bowlin T, Yanofsky S, Barrett RW. (1997) A new cytokine-receptor binding mode revealed by the crystal structure of the IL-1 receptor with an antagonist. Nature, 386 (6621): 194-200. [PMID:9062194]
Immunoglobulin-like family of IL-1 receptors: Interleukin-1 receptor, type I. Last modified on 16/11/2017. Accessed on 12/10/2024. IUPHAR/BPS Guide to PHARMACOLOGY, https://www.guidetomalariapharmacology.org/GRAC/ObjectDisplayForward?objectId=1905.